{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:41:55Z","timestamp":1778794915573,"version":"3.51.4"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Lopinavir, ritonavir, atazanavir, and saquinavir had been reportedly used or suggested for coronavirus disease 2019 (COVID-19) treatment. They may cause electrocardiography changes. We aim to evaluate risk of PR prolongation, QRS widening, and QT prolongation from lopinavir, ritonavir, atazanavir, and saquinavir.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In accordance with preferred reporting items for systematic reviews and meta-analyses guidelines, our search was conducted in PubMed Central, PubMed, EBSCOhost, and ProQuest from inception to June 25, 2020. Titles and abstracts were reviewed for relevance. Cochrane Risk of Bias Tool 2.0 and Downs and Black criteria was used to evaluate quality of studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We retrieved 9 articles. Most randomized controlled trials have low risk of biases while all quasi-experimental studies have a positive rating. Four studies reporting PR prolongation however only 2 studies with PR interval &gt;200\u200ams. One of which, reported its association after treatment with ritonavir-boosted saquinavir treatment while another, during treatment with ritonavir-boosted atazanavir. No study reported QRS widening &gt;120\u200ams with treatment. Four studies reporting QT prolongation, with only one study reaching QT interval &gt;450\u200ams after ritonavir-boosted saquinavir treatment on healthy patients. There is only one study on COVID-19 patients reporting QT prolongation in 1 out of 95 patients after ritonavir-boosted lopinavir treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Limited evidence suggests that lopinavir, ritonavir, atazanavir, and saquinavir could cause PR prolongation, QRS widening, and QT prolongation. Further trials with closer monitoring and assessment of electrocardiography are needed to ascertain usage safety of antivirals in COVID-19 era.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026787","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T19:44:49Z","timestamp":1629143089000},"page":"e26787","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8726-7693","authenticated-orcid":false,"given":"Denio A.","family":"Ridjab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6177-3793","authenticated-orcid":false,"given":"Ignatius","family":"Ivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Budiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwi Jani","family":"Juliawati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","article-title":"Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic","volume":"75","author":"Driggin","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10840-020-00765-3","article-title":"Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence","volume":"59","author":"Asensio","year":"2020","journal-title":"J Interv Card Electrophysiol"},{"issue":"(SI-1)","key":"R3-20250504","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3906\/sag-2004-145","article-title":"Antiviral treatment of COVID-19","volume":"50","author":"\u015eim\u015fek Yavuz","year":"2020","journal-title":"Turk J Med Sci"},{"key":"R4-20250504","first-page":"01","article-title":"Antiviral therapy in management of COVID-19: a system- atic review on current evidence","volume":"8","author":"Yousefifard","year":"2020","journal-title":"Arch Acad Emerg Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1016\/j.tmaid.2020.101646","article-title":"A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease","volume":"35","author":"Hall","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"R6-20250504","first-page":"01","article-title":"Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection","volume":"11","author":"Copertino","year":"2021","journal-title":"J Biomol Struct Dyn"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/cts.12882","article-title":"Risk assessment of drug-induced long QT syndrome for some COVID-19 repurposed drugs","volume":"14","author":"Michaud","year":"2021","journal-title":"Clin Trans Sci"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1345\/aph.1Q422","article-title":"Protease inhibitor\u2013associated QT interval prolongation","volume":"45","author":"Hunt","year":"2011","journal-title":"Ann Pharmacother"},{"key":"R9-20250504","first-page":"01","article-title":"Neuraminidase inhibitors for preventing and treating influenza in adults and children","volume":"4","author":"Jefferson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1371\/journal.pntd.0006034","article-title":"QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient","volume":"11","author":"Chinello","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.3389\/fcvm.2020.00085","article-title":"COVID-19 management and arrhythmia: risks and challenges for clinicians treating patients affected by SARS-CoV-2","volume":"7","author":"Carpenter","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.hrthm.2020.05.024","article-title":"COVID-19 treatments, QT interval and arrhythmic risk: the need for an international Registry on Arrhythmias","volume":"17","author":"Crotti","year":"2020","journal-title":"Heart Rhythm"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ihj.2019.11.259","article-title":"QT prolongation in HIV-positive patients: Review article","volume":"71","author":"Liu","year":"2019","journal-title":"Indian Heart J"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/med.20019","article-title":"QT prolongation through hERG K+ channel blockade: current knowledge and strategies for the early prediction during drug development","volume":"25","author":"Recanatini","year":"2005","journal-title":"Med Res Rev"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/aps.2014.165","article-title":"The protease inhibitor atazanavir blocks hERG K+ channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane","volume":"36","author":"Han","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(05)17950-1","article-title":"Blockade of HERG channels by HIV protease inhibitors","volume":"365","author":"Anson","year":"2005","journal-title":"Lancet"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R18-20250504","first-page":"01","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R19-20250504","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Community Health"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.childyouth.2012.05.012","article-title":"Training health and mental health professionals in motivational interviewing: a systematic review","volume":"34","author":"Barwick","year":"2012","journal-title":"Child Youth Serv Rev"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1468-1293.2006.00382.x","article-title":"A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients","volume":"7","author":"Busti","year":"2006","journal-title":"HIV Med"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.clpt.6100263","article-title":"Ritonavir 100\u200amg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies","volume":"83","author":"Sarapa","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1155\/2011\/393976","article-title":"Cardiac conduction safety during coadministration of artemether-lumefantrine and lopinavir\/ritonavir in hiv-infected ugandan adults","volume":"2011","author":"Byakika-Kibwika","year":"2011","journal-title":"Chemother Res Pract"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cpt.1303","article-title":"Assessment of multi ion channel block in a phase i randomized study design: results of the Ci PA phase I ECG biomarker validation study","volume":"105","author":"Vicente","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1345\/aph.1G524","article-title":"Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients","volume":"40","author":"Baker","year":"2006","journal-title":"Ann Pharmacother"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1310\/hct1005-328","article-title":"Electrocardiogram abnormalities with atazanavir and lopinavir\/ritonavir","volume":"10","author":"Rathbun","year":"2009","journal-title":"HIV Clin Trials"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0091270011400071","article-title":"Thorough QT\/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants","volume":"52","author":"Zhang","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40268-015-0087-7","article-title":"Effect of a modified saquinavir\/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-Na\u00efve HIV-1-infected patients","volume":"15","author":"Boffito","year":"2015","journal-title":"Drugs RD"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/1740774517697919","article-title":"Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization","volume":"14","author":"Peterson","year":"2017","journal-title":"Clin Trials"},{"key":"R32-20250504","first-page":"61134","article-title":"International conference on harmonisation; guidance on E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability","volume":"70","year":"2005","journal-title":"Notice Fed Regist"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/QAI.0000000000000411","article-title":"Efficacy of second-line antiretroviral therapy among people living with HIV\/AIDS in Asia: results from the TREAT Asia HIV Observational Database","volume":"68","author":"Boettiger","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/TCRM.S3285","article-title":"Lopinavir\/ritonavir in the treatment of HIV-1 infection: a review","volume":"4","author":"Chandwani","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2217\/fvl.10.89","article-title":"Atazanavir\/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults","volume":"6","author":"Achenbach","year":"2011","journal-title":"Future Virol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00002030-199902040-00009","article-title":"Ritonavir and saquinavir combination therapy for the treatment of HIV infection","volume":"13","author":"Cameron","year":"1999","journal-title":"AIDS Lond Engl"},{"key":"R38-20250504","first-page":"95","article-title":"HIV protease inhibitors: a review of molecular selectivity and toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"HIVAIDS Auckl NZ"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:42:40Z","timestamp":1746337360000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026787"}},"subtitle":["A systematic review"],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":37,"journal-issue":{"issue":"31","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026787","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,6]]},"assertion":[{"value":"2020-07-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}